Comparison of pemetrexed plus cisplatin versus pemetrexed plus carboplatin in the initial treatment of locally advanced or metastatic non-small cell lung cancer.

Abstract

e18067 Background: The combination of pemetrexed plus cisplatin (PC) was recently approved in the initial treatment of advanced stage non-small cell lung cancer (NSCLC). Studies reported comparable efficacy of the combination pemetrexed plus carboplatin (PCar) in the same setting. METHODS We assessed 69 patients with locally advanced or metastatic NSCLC… (More)

Topics

Cite this paper

@article{Pereira2011ComparisonOP, title={Comparison of pemetrexed plus cisplatin versus pemetrexed plus carboplatin in the initial treatment of locally advanced or metastatic non-small cell lung cancer.}, author={Adenilson Pereira and Ronaldo Lessa and Celso Eduardo Souza and Fabiana A. Pinto and D M Gagliato and Elizabete Silva dos Santos and Mario Fanelli and Jos{\'e} Augusto Rinck and Aldo Lourenço Abbade Dettino and Ulisses Ribaldo Nicolau and Ludmilla Thom{\'e} Domingos Chinen and V.C.C. de Lima and J. R. Pereira and M R D S Cruz}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2011}, volume={29 15_suppl}, pages={e18067} }